Overview

Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2032-12-01

Target enrollment:

Participant gender:

Summary

To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

regorafenib